A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in Obese Subjects
Latest Information Update: 28 Oct 2025
At a glance
- Drugs HRS-7535 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Shandong Suncadia Medicine
Most Recent Events
- 16 Jun 2025 According to Kailera Therapeutics media release, data from this trial will be presented at the 85th Scientific Sessions of the American Diabetes Association (ADA), and will be published online in the journal Diabetes
- 09 Apr 2025 Status changed from not yet recruiting to completed.
- 13 Feb 2024 New trial record